公开(公告)号：US20090130715A1

公开(公告)日：2009-05-21

申请号：US12284605

申请日：2008-09-22

申请人： Vahe Bedian ,  Ronald P. Gladue ,  Jose Corvalan ,  Xiao-Chi Jia ,  Xiao Feng

发明人： Vahe Bedian ,  Ronald P. Gladue ,  Jose Corvalan ,  Xiao-Chi Jia ,  Xiao Feng

IPC分类号： C12N15/13 ,  C12N15/63 ,  C12N5/10 ,  C12N1/21 ,  C12N1/19 ,  C12P21/00

CPC分类号： C07K16/2866 ,  A01K2217/05 ,  A61K39/3955 ,  A61K45/06 ,  A61K48/00 ,  A61K2039/505 ,  A61N5/062 ,  A61N5/10 ,  C07K16/2878 ,  C07K16/40 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/75 ,  C07K2317/92

摘要： The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also relates to human anti-CD40 antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-CD40 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-CD40 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-CD40 antibodies. The invention also relates to transgenic animals comprising nucleic acid molecules of the present invention.

摘要翻译： 本发明涉及与CD40，优选人CD40特异性结合并且作为CD40激动剂起作用的抗体及其抗原结合部分。 本发明还涉及人抗CD40抗体及其抗原结合部分。 本发明还涉及嵌合，双特异性，衍生的单链抗体或融合蛋白的部分的抗体。 本发明还涉及衍生自人抗CD40抗体的分离的重链和轻链免疫球蛋白和编码这种免疫球蛋白的核酸分子。 本发明还涉及制备人抗CD40抗体的方法，包含这些抗体的组合物和使用抗体和组合物进行诊断和治疗的方法。 本发明还提供使用编码包含人抗-CD40抗体的重和/或轻免疫球蛋白分子的核酸分子的基因治疗方法。 本发明还涉及包含本发明的核酸分子的转基因动物。

公开(公告)号：US20050069539A1

公开(公告)日：2005-03-31

申请号：US10917073

申请日：2004-08-12

申请人： Bruce Cohen ,  Vahe Bedian

发明人： Bruce Cohen ,  Vahe Bedian

IPC分类号： A61K39/395 ,  C07K16/28 ,  C07K16/18

CPC分类号： C07K16/2863 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/567

摘要： The present invention relates to antibodies, which are directed to the human IGF-1 receptor (IGF-1R) and are to be administered for the treatment of cancer. The antibodies of the present invention have been altered to comprise antibodies with one or more selected germlne framework amino acid residues which replace one or more corresponding somatically mutated residues in the variable region of the unaltered antibody. The modification results in the framework region mutations converted to germline. The modification results in a reduced propensity for the antibody to elicit an immune response (reduced immunogenicity) following administration to a human subject.

摘要翻译： 本发明涉及针对人IGF-1受体（IGF-1R）并被用于治疗癌症的抗体。 已经将本发明的抗体改变为包含具有一个或多个所选择的生物框架氨基酸残基的抗体，其替代未改变抗体的可变区中的一个或多个相应的体细胞突变残基。 修饰导致框架区突变转化为种系。 修饰导致抗体在施用于人受试者后引起免疫应答（降低的免疫原性）降低的倾向。

公开(公告)号：US08398975B2

公开(公告)日：2013-03-19

申请号：US12782335

申请日：2010-05-18

申请人： Julie Rinkenberger ,  Ian Foltz ,  Avril Alfred ,  Simon Thomas Barry ,  Vahe Bedian

发明人： Julie Rinkenberger ,  Ian Foltz ,  Avril Alfred ,  Simon Thomas Barry ,  Vahe Bedian

IPC分类号： A61K39/395 ,  C07K16/00 ,  C07K16/46 ,  C07K16/28

CPC分类号： C07K16/2839 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/76 ,  C07K2317/92 ,  C12N5/0686 ,  C12N2501/998

摘要： Targeted binding agents, such antibodies directed to the antigen αVβ6 and uses of such agents are described. In particular, fully human monoclonal antibodies directed to the antigen αVβ6 are disclosed. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3 are disclosed. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also disclosed.

摘要翻译： 描述了靶向结合剂，针对抗原αV和bgr的这种抗体以及这些药剂的用途。 特别地，公开了针对抗原αV和bgr的完全人单克隆抗体。 编码的核苷酸序列和包含重链和轻链免疫球蛋白分子的氨基酸序列，特别是对应于跨越框架区和/或互补决定区（CDR）的连续重链和轻链序列的序列，特别是从FR1至FR4或CDR1至CDR3 被披露。 还公开了表达这种免疫球蛋白分子和单克隆抗体的杂交瘤或其它细胞系。

公开(公告)号：US08388971B2

公开(公告)日：2013-03-05

申请号：US13471395

申请日：2012-05-14

申请人： Vahe Bedian ,  Ronald P. Gladue ,  Jose Ramon Corvalan ,  Xiao-Chi Jia ,  Xiao Feng

发明人： Vahe Bedian ,  Ronald P. Gladue ,  Jose Ramon Corvalan ,  Xiao-Chi Jia ,  Xiao Feng

IPC分类号： A61K39/395 ,  C07K16/28

CPC分类号： C07K16/2866 ,  A01K2217/05 ,  A61K39/3955 ,  A61K45/06 ,  A61K48/00 ,  A61K2039/505 ,  A61N5/062 ,  A61N5/10 ,  C07K16/2878 ,  C07K16/40 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/75 ,  C07K2317/92

摘要： The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also relates to human anti-CD40 antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-CD40 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-CD40 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-CD40 antibodies. The invention also relates to transgenic animals comprising nucleic acid molecules of the present invention.

公开(公告)号：US20120244167A1

公开(公告)日：2012-09-27

申请号：US13458820

申请日：2012-04-27

申请人： Vahe Bedian ,  Madhav Narasimha Devalaraja ,  Ian Foltz ,  Mary Haak-Frendscho ,  Sirid-Aimée Kellermann ,  Joseph Edwin Low ,  James Leslie Mobley

发明人： Vahe Bedian ,  Madhav Narasimha Devalaraja ,  Ian Foltz ,  Mary Haak-Frendscho ,  Sirid-Aimée Kellermann ,  Joseph Edwin Low ,  James Leslie Mobley

IPC分类号： A61K39/395 ,  A61P29/00 ,  A61P35/00 ,  C12N1/19 ,  A61P9/00 ,  C12N5/16 ,  C12N5/10 ,  C12N1/21 ,  C07K16/24 ,  A61P25/00

CPC分类号： C07K16/243 ,  A61K38/193 ,  A61K39/395 ,  A61K2039/505 ,  C07K16/24 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  G06Q30/02 ,  G06Q30/0601 ,  G06Q40/04 ,  G06Q50/12 ,  Y02A50/412

摘要： The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to a M-CSF, preferably human M-CSF, and that function to inhibit a M-CSF. The invention also relates to human anti-M-CSF antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-M-CSF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-M-CSF antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-M-CSF antibodies. The invention also relates to transgenic animals and transgenic plants comprising nucleic acid molecules of the present invention.

摘要翻译： 本发明涉及特异性结合M-CSF，优选人M-CSF的抗体及其抗原结合部分，其功能是抑制M-CSF。 本发明还涉及人抗M-CSF抗体及其抗原结合部分。 本发明还涉及嵌合，双特异性，衍生的单链抗体或融合蛋白的部分的抗体。 本发明还涉及衍生自人抗M-CSF抗体的分离的重链和轻链免疫球蛋白和编码这种免疫球蛋白的核酸分子。 本发明还涉及制备人抗M-CSF抗体的方法，包含这些抗体的组合物和使用该抗体和组合物进行诊断和治疗的方法。 本发明还提供使用编码包含人抗M-CSF抗体的重和/或轻免疫球蛋白分子的核酸分子的基因治疗方法。 本发明还涉及包含本发明的核酸分子的转基因动物和转基因植物。

公开(公告)号：US20120195905A1

公开(公告)日：2012-08-02

申请号：US13446637

申请日：2012-04-13

申请人： Vahe Bedian ,  David Jenkins ,  Ian FOLTZ

发明人： Vahe Bedian ,  David Jenkins ,  Ian FOLTZ

IPC分类号： A61K39/395 ,  C07K16/18 ,  A61P35/00 ,  C12N15/13

CPC分类号： C07K16/28 ,  A61K39/395 ,  A61K39/39533 ,  A61K39/3955 ,  A61K2039/505 ,  C07H21/04 ,  C07K14/475 ,  C07K16/22 ,  C07K2317/565 ,  C07K2317/92

摘要： The invention relates to targeted binding agents against DLL4 and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to DLL4. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of DLL-4 and as diagnostics.

摘要翻译： 本发明涉及针对DLL4的靶向结合剂及其用途。 更具体地，本发明涉及针对DLL4的完全人单克隆抗体。 所描述的靶向结合剂可用于治疗与DLL-4的活性和/或过量产生相关的疾病和作为诊断。

公开(公告)号：US07626012B2

公开(公告)日：2009-12-01

申请号：US12284605

申请日：2008-09-22

申请人： Vahe Bedian ,  Ronald P. Gladue ,  Jose Corvalan ,  Xiao-Chi Jia ,  Xiao Feng

发明人： Vahe Bedian ,  Ronald P. Gladue ,  Jose Corvalan ,  Xiao-Chi Jia ,  Xiao Feng

IPC分类号： C12N15/13 ,  C12N15/12 ,  C12N5/12 ,  C12N15/63

CPC分类号： C07K16/2866 ,  A01K2217/05 ,  A61K39/3955 ,  A61K45/06 ,  A61K48/00 ,  A61K2039/505 ,  A61N5/062 ,  A61N5/10 ,  C07K16/2878 ,  C07K16/40 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/75 ,  C07K2317/92

摘要： The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also relates to human anti-CD40 antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-CD40 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-CD40 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-CD40 antibodies. The invention also relates to transgenic animals comprising nucleic acid molecules of the present invention.

摘要翻译： 本发明涉及与CD40，优选人CD40特异性结合并且作为CD40激动剂起作用的抗体及其抗原结合部分。 本发明还涉及人抗CD40抗体及其抗原结合部分。 本发明还涉及嵌合，双特异性，衍生的单链抗体或融合蛋白的部分的抗体。 本发明还涉及衍生自人抗CD40抗体的分离的重链和轻链免疫球蛋白和编码这种免疫球蛋白的核酸分子。 本发明还涉及制备人抗CD40抗体的方法，包含这些抗体的组合物和使用抗体和组合物进行诊断和治疗的方法。 本发明还提供了使用编码包含人抗-CD40抗体的重和/或轻免疫球蛋白分子的核酸分子的基因治疗方法。 本发明还涉及包含本发明的核酸分子的转基因动物。

公开(公告)号：US07563442B2

公开(公告)日：2009-07-21

申请号：US11213575

申请日：2005-08-26

申请人： Vahe Bedian ,  Ronald P Gladue ,  Jose Corvalan ,  Xiao-Chi Jia ,  Xiao Feng

发明人： Vahe Bedian ,  Ronald P Gladue ,  Jose Corvalan ,  Xiao-Chi Jia ,  Xiao Feng

IPC分类号： A61K39/395 ,  C07K16/28

CPC分类号： C07K16/2866 ,  A01K2217/05 ,  A61K39/3955 ,  A61K45/06 ,  A61K48/00 ,  A61K2039/505 ,  A61N5/062 ,  A61N5/10 ,  C07K16/2878 ,  C07K16/40 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/75 ,  C07K2317/92

摘要： The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also relates to human anti-CD40 antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-CD40 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-CD40 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-CD40 antibodies. The invention also relates to transgenic animals comprising nucleic acid molecules of the present invention.

摘要翻译： 本发明涉及与CD40，优选人CD40特异性结合并且作为CD40激动剂起作用的抗体及其抗原结合部分。 本发明还涉及人抗-CD40抗体及其抗原结合部分。 本发明还涉及嵌合，双特异性，衍生的单链抗体或融合蛋白的部分的抗体。 本发明还涉及衍生自人抗CD40抗体的分离的重链和轻链免疫球蛋白和编码这种免疫球蛋白的核酸分子。 本发明还涉及制备人抗CD40抗体的方法，包含这些抗体的组合物和使用抗体和组合物进行诊断和治疗的方法。 本发明还提供使用编码包含人抗-CD40抗体的重和/或轻免疫球蛋白分子的核酸分子的基因治疗方法。 本发明还涉及包含本发明的核酸分子的转基因动物。

公开(公告)号：US07537762B2

公开(公告)日：2009-05-26

申请号：US11517530

申请日：2006-09-06

申请人： Michael Aidan North ,  Karin Kristina Amundson ,  Vahe Bedian ,  Shelley Sims Belouski ,  Dana Dan Hu-Lowe ,  Xin Jiang ,  Shannon Marie Karlicek ,  Sirid Aimee Kellerman ,  James Arthur Thomson ,  Jianying Wang ,  Grant Raymond Wickman ,  Jingchuan Zhang

发明人： Michael Aidan North ,  Karin Kristina Amundson ,  Vahe Bedian ,  Shelley Sims Belouski ,  Dana Dan Hu-Lowe ,  Xin Jiang ,  Shannon Marie Karlicek ,  Sirid Aimee Kellerman ,  James Arthur Thomson ,  Jianying Wang ,  Grant Raymond Wickman ,  Jingchuan Zhang

IPC分类号： A61K39/395 ,  C07K16/40

CPC分类号： C07K16/40 ,  A61K2039/505 ,  C07K16/2863 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92

摘要： The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to the extracellular domain (ECD) of activin receptor-like kinase-1 (ALK-1) and that function to abrogate the ALK-1/TGF-beta-1/Smad1 signaling pathway. The invention also relates to heavy and light chain immunoglobulins derived from human anti-ALK-1 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-ALK-1 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.

摘要翻译： 本发明涉及包含结合活化素受体样激酶-1（ALK-1）的细胞外结构域（ECD）的人抗体及其抗原结合部分的抗体，其功能是消除ALK-1 / TGF-β -1 / Smad1信号通路。 本发明还涉及源自人抗ALK-1抗体的重链和轻链免疫球蛋白和编码这种免疫球蛋白的核酸分子。 本发明还涉及制备人抗ALK-1抗体的方法，包含这些抗体的组合物和使用抗体和组合物的方法。 本发明还涉及包含本发明的核酸分子的转基因动物或植物。

公开(公告)号：US07338660B2

公开(公告)日：2008-03-04

申请号：US11211917

申请日：2005-08-25

申请人： Vahe Bedian ,  Ronald P Gladue ,  Jose Corvalan ,  Xiao-Chi Jia ,  Xiao Feng

发明人： Vahe Bedian ,  Ronald P Gladue ,  Jose Corvalan ,  Xiao-Chi Jia ,  Xiao Feng

IPC分类号： A61K39/395 ,  C07K16/28

CPC分类号： C07K16/2866 ,  A01K2217/05 ,  A61K39/3955 ,  A61K45/06 ,  A61K48/00 ,  A61K2039/505 ,  A61N5/062 ,  A61N5/10 ,  C07K16/2878 ,  C07K16/40 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/75 ,  C07K2317/92

摘要： The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also relates to human anti-CD40 antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-CD40 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-CD40 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-CD40 antibodies. The invention also relates to transgenic animals comprising nucleic acid molecules of the present invention.

摘要翻译： 本发明涉及与CD40，优选人CD40特异性结合并且作为CD40激动剂起作用的抗体及其抗原结合部分。 本发明还涉及人抗CD40抗体及其抗原结合部分。 本发明还涉及嵌合，双特异性，衍生的单链抗体或融合蛋白的部分的抗体。 本发明还涉及衍生自人抗CD40抗体的分离的重链和轻链免疫球蛋白和编码这种免疫球蛋白的核酸分子。 本发明还涉及制备人抗CD40抗体的方法，包含这些抗体的组合物和使用抗体和组合物进行诊断和治疗的方法。 本发明还提供使用编码包含人抗-CD40抗体的重和/或轻免疫球蛋白分子的核酸分子的基因治疗方法。 本发明还涉及包含本发明的核酸分子的转基因动物。